Investing in Home-Based Care

Partnering with exceptional management teams to improve quality of care and better serve patients, families, and communities.

About Homevale Partners

Homevale Partners LLC is an investment firm focused on the acquisition and operations of home and community-based care healthcare services businesses.

The firm's founder, Andrew Bates, brings deep healthcare operating experience from his time as COO and CFO at Medalogix, a home health and hospice clinical decision support platform, where he helped scale the company and guide its 2025 sale to Berkshire Partners. Prior to Medalogix, Andrew served as a Managing Director at Coliseum Capital Management, where he partnered with and invested in businesses across the home-based care continuum, with an emphasis on services that deliver high-quality outcomes while decreasing costs for patients where possible.

Andrew's blend of experience investing and operating home healthcare businesses has shaped Homevale's approach to partnering with management teams to improve quality of care and reducing friction where possible to lower costs for patients.

The firm is committed to long-term ownership, with the goal of acquiring exceptional home-based care companies, investing in their people, and scaling responsibly to better serve patients, families, and referral partners.

Home Healthcare Track Record

Homevale's founder and partners have invested in and operated businesses across the home-based care continuum, from the nation's largest providers to high-growth technology platforms.

🏥

LHC Group

Home Health & Hospice

A Homevale partner was a significant investor in LHC Group, helping drive its growth into the largest home health and hospice operator in the United States, with 960+ locations across 37 states. Acquired by UnitedHealth Group/Optum for $5.4 billion in 2023.

$5.4B Acquisition by
UnitedHealth/Optum
🧬

Medalogix

Clinical Decision Support

A Homevale partner acquired and merged this AI-powered clinical decision support platform for home health and hospice, then served as a senior executive helping scale it to serve approximately one-third of all Medicare home health and hospice recipients. The business was sold for an undisclosed sum in 2025.

375K+ Daily beneficiaries
supported
💉

BioScrip

Home Infusion

A Homevale partner was an early investor in BioScrip, helping drive its growth as a national home infusion therapy provider. BioScrip later merged with Option Care in 2019 to form Option Care Health (NASDAQ: OPCH), now the largest independent home infusion services provider in the U.S.

$5.1B Combined market cap
(Option Care Health)
🩺

CureCare

Infusion Nursing

A Homevale partner was the largest investor in CureCare, an independent infusion nursing services provider delivering in-home IV therapy across multiple states as a cost-effective alternative to hospital-based infusion.

8+ States with active
nursing operations

Focus Areas

🏠

Private Duty

In-home personal care and support services for individuals and families.

🤝

Hospice

Compassionate end-of-life care focused on comfort and dignity.

🏡

Home & Community-Based Services

Community-centered care enabling patients to thrive at home.

📈

Adjacent Sectors

Operational enhancements that create value across the care continuum.